SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-063101
Filing Date
2021-12-02
Accepted
2021-12-02 16:15:11
Documents
9
Period of Report
2021-12-02

Document Format Files

Seq Description Document Type Size
1 FORM 6-K ea151533-6k_biondvax.htm 6-K 11393
2 PRESS RELEASE DATED NOVEMBER 11, 2021 ea151533ex99-1_biondvax.htm EX-99.1 88388
3 BIONDVAX PHARMACEUTICALS LTD. UNAUDITED INTERIM FINANCIAL STATEMENTS FOR THE PER ea151533ex99-2_biondvax.htm EX-99.2 269242
4 GRAPHIC image_001.jpg GRAPHIC 7288
5 GRAPHIC image_001.gif GRAPHIC 121
6 GRAPHIC image_002.gif GRAPHIC 121
7 GRAPHIC image_003.gif GRAPHIC 121
8 GRAPHIC image_004.gif GRAPHIC 121
9 GRAPHIC image_005.gif GRAPHIC 121
  Complete submission text file 0001213900-21-063101.txt   381829
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 211466776
SIC: 2836 Biological Products, (No Diagnostic Substances)